A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40 mg Monotherapy. - TAKEDA TAK-491CLD_307

Takeda0 个研究点目标入组 28 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•The subject has grade 2-3 essential hypertension which is not adequately controlled as defined by mean, trough,
•sitting, clinic SBP: >=160 to <=180 mm Hg in subjects who have not received any antihypertensive medication in the 14 days prior to Visit 1.
•- >=150 to <=170 mm Hg in subjects taking 1 antihypertensive medication at Visit 1.
•- >=140 to <=160 mm Hg in subjects taking 2 antihypertensive medications at Visit 1.
•The subject has clinical laboratory test results (clinical chemistry, hematology, and complete urinalysis) within
•the reference range for the testing laboratory or the investigator does not consider the results to be clinically relevant for precluding entry in to the study in this hypertensive population.
•The subject is willing to discontinue current antihypertensive medications.
•The subject must have a post-placebo run-in, 24-hour mean SBP by ABPM of 140-175 mm Hg inclusive, and a sitting clinic SBP measurement of 160 to 190 mm Hg inclusive (determined by the mean of 3 sitting, trough, measurements on Day -29) to qualify for entry in to the 4 week single-blind TAK-491 40 mg monotherapy treatment testing period.
•The subject does not achieve target blood pressure (defined as clinic SBP >=140 mm Hg as determined by the mean of 3 sitting, trough, measurements) following 4 weeks single-blind treatment with TAK-491 40 mg monotherapy at Day -1, prior to randomization to double-blind treatment.

•The subject has clinic DBP >110 mm Hg.
•The subject*s 3 SBP measurements at screening differ by more than 15 mm Hg (confirmed by a second set of three measurements).
•The subject is currently treated with more than 2 antihypertensive medications.
•The subject has secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing*s syndrome).
•The subject has any history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, persistent or permanent atrial fibrillation or transient ischemic attack.
•The subject has clinically significant cardiac conduction defects (eg, third-degree atrioventricular block, sick sinus syndrome).
•The subject has severe renal dysfunction or disease [based on estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 at screening].
•The subject has poorly-controlled type 1 or 2 diabetes mellitus (hemoglobin A1c [HbA1c] >8.5%) at Screening

发起方

Takeda